Michael Bretthauer
Led NordICC, the first randomised trial of screening colonoscopy, which found smaller benefits than many expected.
Overview
Michael Bretthauer (University of Oslo) was principal investigator of NordICC, the Nordic and Polish randomised trial of invitation to screening colonoscopy, whose 2022 result of an 18% reduction in colorectal cancer incidence and no significant mortality benefit in the intention-to-screen analysis reset expectations for colonoscopy screening. He leads the Clinical Effectiveness Research Group and works on screening quality and trial methodology.
| Title | Journal | Year |
|---|---|---|
| Effect of colonoscopy screening on risks of colorectal cancer and related death (NordICC) | NEJM | 2022 |
| Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial | JAMA Internal Medicine | 2016 |
Pages like this
not linked directly; found by shared links- IdeaPersonalised stool-test cut-offs by age, sex and prior results
Shares NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected, Colorectal cancer.
- PersonAngelita Habr-Gama
Shares Colorectal cancer and the tag colorectal.
- PersonAimery de Gramont
Shares Colorectal cancer and the tag colorectal.
- PersonTheodore R. Levin
Shares Colorectal cancer and the tag screening.
- PersonHarry J. de Koning
Shares the tags screening, epidemiology.
- PersonMark Schiffman
Shares the tags screening, epidemiology.
- PersonSigurdur Y. Kristinsson
Shares the tags screening, epidemiology.
- Key paperMinnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third
Shares NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected, Colorectal cancer.